# USANA Health Sciences account plan

> USANA Health Sciences makes science-based nutritional supplements sold by direct selling and Hiya, with $925.3 million FY2025 net sales.

## At a glance

USANA Health Sciences (NYSE: USNA, Salt Lake City, Utah) develops and manufactures science-based nutritional supplements, functional foods and personal care products. It historically sold only through independent Brand Partners and Preferred Customers, and now runs an omni-channel platform after acquiring Rise and a 78.85% stake in Hiya Health Products: direct selling, direct-to-consumer, Amazon and retail. FY2025 net sales were $925.3 million (+8.3%), but net earnings attributable to USANA fell 74.4% to $10.8 million; China was approximately 41.3% of net sales. It had approximately 1,570 employees (FTE) in 22 countries.

## Business units

- **Core Nutritional** ($775.5 million, 83.8% of FY2025 net sales): USANA-branded supplements, foods and Celavive skincare sold through Brand Partners and Preferred Customers, 90.8% outside the United States; Greater China is the largest region. Active Customers fell to approximately 356,000 in Q3 2026 (-8.2%), and Q3 2026 sales were $170.7 million (-3.1%).
- **Hiya** ($132.0 million, 14.3% of FY2025 net sales): Children's vitamins sold mainly by subscription in the United States, now also in Canada, the UK, Target and Amazon. Q3 2026 sales rose 2.3% to $31.5 million with approximately 195,500 active Monthly Subscribers; a $29.1 million goodwill impairment was taken in Q2 2026.
- **Rise** ($20.7 million nine-month 2026 net sales): Protein bars and protein drinks, including Protein Pop (68% of Rise sales), sold to national and club retailers. Nine-month sales rose 94.4%, but Q3 2026 sales fell 44.8% to $3.6 million and the outlook was lowered as club orders were lumpy.

## Strategic priorities

- **Omnichannel transformation**: Management aims to evolve USANA from a single channel direct selling company into a diversified omnichannel health and wellness company, which it also frames as reducing dependence on China.
- **Grow active customers**: Growing the active customer base is the top priority, through brand investment, Brand Partner plan adjustments phased in through 2027, and women's and kids' product launches in 2027.
- **Technology modernisation and AI**: USANA plans to modernise core systems by adopting best-in-practice third-party platforms and to use AI, rather than building everything in-house.
- **Scale Hiya and Rise**: Hiya's sales outlook was raised to $130 million with club retail entry planned early Q1 2027; Rise will be in about 4,100 Target and grocery stores by year end.
- **Operational efficiency**: The Q4 2025 cost realignment affected about 10% of the workforce for roughly $10 million of net savings, and more manufacturing is being brought in-house.

## Latest results

In Q3 2026 (quarter ended October 3, 2026), net sales fell 3.6% to $205.9 million (5.6% excluding currency) and the net loss attributable to USANA was $5.6 million, or $(0.30) per diluted share. Core Nutritional sales fell 3.1% while Hiya grew 2.3% and Rise fell 44.8%. Nine-month net sales were $679.4 million, with a diluted loss per share of $(1.05) mainly due to the Hiya goodwill impairment. The FY2026 outlook is net sales approaching $900 million and adjusted EBITDA of approximately $77 million, down from $80.5 million.

## Investments and deals

- **In-house manufacturing**: Hiya products and powdered drink mixes are moving into USANA's own facilities, with more personal care and skincare made in-house.
- **Inventory for retail expansion**: Inventory rose $35 million to $107 million at the end of 2025, about 80% of it for Rise (Protein Pop at Costco) and Hiya (Target, Canada, UK).
- **Castle Hill sale**: The sale of the Castle Hill, New South Wales office and warehouse settled October 12, 2026, with an estimated pre-tax gain of $8,230 thousand in Q4 2026.
- **Acquisitions**: USANA expects to keep pursuing health and wellness acquisitions for vertical integration, category, channel and geographic expansion.

## Challenges and risks

- **Shrinking core customer base**: Core nutritional active Customers fell 14.8% in FY2025 and 8.2% in Q3 2026, with every region outside Southeast Asia Pacific declining in constant currency.
- **China dependence and regulation**: Greater China is the largest market, BabyCare's model has not been approved by the Chinese government, and US-China tensions and tariffs are named risks.
- **High tax rate**: The effective tax rate was 72.4% in FY2025 because revenue and costs sit in different geographies; guidance for 2026 was 55%-60%.
- **Venture profitability**: Hiya's SG&A rose to 86.2% of segment sales on advertising, and Rise had a negative gross margin in Q3 2026; management is not satisfied with Rise's results.

## What leadership says

> "we must move with greater speed, focus, relevancy, and precision" — Kevin Guest, Chairman and Chief Executive Officer, Q4 and fiscal 2025 earnings call, February 18, 2026

> "Growing our active customer base remains our top priority." — Kevin Guest, Chairman and Chief Executive Officer, Q3 2026 earnings call, November 4, 2026

> "we're not satisfied with Rise Wellness' results" — Kevin Guest, Chairman and Chief Executive Officer, Q3 2026 earnings call, November 4, 2026


## Where a supplier can help

- **Third-party IT platforms and AI**: Core-system modernisation explicitly favours outside platforms and AI, opening doors for commerce, CRM, ERP and AI vendors.
- **Customer acquisition and retention**: Growing active customers and Hiya subscriber retention are top priorities; loyalty, marketing analytics and digital acquisition tools fit.
- **Retail and club distribution**: Hiya and Rise expansion into Target, Costco and club stores, with lumpy orders, calls for retail execution and demand-planning support.
- **Manufacturing and supply chain**: Bringing Hiya and other products in-house and managing elevated inventory create needs for equipment, packaging and inventory tools.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [USANA Health Sciences Form 10-K for fiscal year 2025 (ended January 3, 2026)](https://www.sec.gov/Archives/edgar/data/896264/000089626426000021/usna-20260103.htm)

Annual report · 2026-03-16

- USANA develops and manufactures science-based nutritional supplements, functional foods and personal care products; FY2025 net sales were $925.3 million (+8.3%), with operations in 25 geographic markets and approximately 1,570 employees (FTE) in 22 countries.
- Two reportable segments in FY2025: Core nutritional (direct selling via Brand Partners and Preferred Customers, $775.5 million, 83.8% of sales) and Hiya direct-to-consumer (children's vitamins, $132.0 million, 14.3%); an "other" category (Rise protein bars/drinks and Oola) added $17.8 million (segment figures rounded from the 10-K tables in thousands).
- China is the largest market: approximately 41.3% of net sales and 49.9% of core nutritional active Customers; net sales outside the United States were 75.7% of consolidated net sales.
- Core business shrinking: core nutritional active Customers fell 14.8% to approximately 387,000; core net sales (with other) were $793.3 million, down 6.9%, partly offset by a 4.4% increase in average spend per customer.
- Profitability fell sharply: earnings from operations 4.0% of sales (7.7% in 2024); net earnings attributable to USANA down 74.4% to $10.8 million; diluted EPS $0.58 vs $2.19; effective tax rate 72.4%.
- Q4 2025 cost realignment and rightsizing: one-time charge of $6,463 thousand, plus a $6,527 thousand non-cash goodwill impairment.
- Strategy: move from a single direct-selling channel to an omni-channel platform (direct selling, direct-to-consumer, Amazon, retail); enhanced Brand Partner Compensation Plan rolled out in Q3 2025; Hiya expanding into Canada, the UK and retail in 2026, with Hiya products moving to in-house manufacturing.
- Technology: plans to accelerate modernisation of core systems and to "strategically leverage leading third-party IT platforms to move faster and more efficiently".
- Leadership: Kevin Guest reassumed the CEO role in January 2026 and remains Chairman; G. Douglas Hekking is CFO, Walter Noot COO, Brent Neidig Chief Commercial Officer, Kathryn Armstrong Chief Scientific Officer.
- Key risks: China direct-selling regulation (BabyCare's model has not been approved by the Chinese government), US-China trade tensions and tariffs, currency, Brand Partner retention, and integration of acquisitions such as Hiya.

### [USANA Health Sciences Form 10-Q for Q3 2026 (quarter ended October 3, 2026)](https://www.sec.gov/Archives/edgar/data/896264/000089626426000070/usna-20261003.htm)

Interim report · 2026-11-12

- Q3 2026 net sales $205.9 million, down 3.6% (down 5.6% excluding currency); net loss attributable to USANA $5.6 million vs $6.5 million a year earlier; diluted loss per share $(0.30).
- USANA now reports three segments: Core Nutritional (approximately 83% of nine-month sales), Hiya and Rise.
- Core Nutritional Q3 net sales $170.7 million, down 3.1% (5.5% in constant currency); active Customers down 8.2% to approximately 356,000, with Greater China at 192,000 (-8.6%).
- Hiya Q3 net sales $31.5 million, up 2.3%; approximately 195,500 active Monthly Subscribers; Hiya now sells in the US, Canada and the UK and entered retail in Q1 2026; a $29.1 million non-cash goodwill impairment was taken on Hiya in Q2 2026.
- Rise Q3 net sales $3.6 million, down 44.8%, but nine-month sales up 94.4% to $20.7 million on the Protein Pop launch (Protein Pop is 68% of Rise sales).
- Core Nutritional SG&A fell to 33.9% of segment sales on cost realignment savings; Hiya SG&A jumped to 86.2% of segment sales on higher advertising.
- Cash $178.9 million and no outstanding debt on the $75 million credit facility; China remitted a $62.3 million dividend to the US; credit covenants were eased by an amendment on September 30, 2026.
- Sale of the Castle Hill (Australia) facility settled October 12, 2026: net proceeds about $16,080 thousand and an expected pre-tax gain of $8,230 thousand in Q4 2026.

### [USANA Q4 and fiscal 2025 earnings call (February 18, 2026)](https://www.fool.com/earnings/call-transcripts/2026/02/18/usana-usna-q4-2025-earnings-call-transcript/)

Executive talk · Kevin Guest, Chairman and Chief Executive Officer · 2026-02-18

- First call after Kevin Guest's return as CEO; he says the clear message from leaders and Brand Partners is "we must move with greater speed, focus, relevancy, and precision".
- Six priorities: global brand positioning as a "modern, science-driven nutritional products company" through an omnichannel platform, customer and Brand Partner experience, sales momentum, product innovation, operational efficiency, and accountability.
- FY2026 outlook: consolidated net sales growth of about 4% at the midpoint, driven by the ventures Rise Wellness and Hiya; Rise expected to be roughly breakeven.
- Technology modernisation will move to best-in-practice third-party platforms and AI; the incremental investment is not yet in the outlook.
- Inventory rose $35 million (48%) to $107 million, about 80% of it for Rise Wellness (Protein Pop at Costco) and Hiya (Target, Canada, UK, in-house manufacturing).
- Cost realignment affected about 10% of the workforce, with roughly $10 million of net savings, mainly in SG&A.
- Effective tax rate guidance 55%-60% because revenue and costs sit in different geographies; Guest frames the omnichannel push as diversifying revenue away from China.

### [USANA Q3 2026 earnings call (November 4, 2026)](https://www.earningswhispers.com/transcript/USNA/Q32026)

Executive talk · Kevin Guest, Chairman and Chief Executive Officer · 2026-11-04

- Guest calls Q3 2026 "a mixed quarter"; the strategy is to evolve USANA "from a single channel direct selling company into a diversified omnichannel health and wellness company built on consumer acquisition and loyalty".
- Core nutrition: active customers down 8% year over year, Greater China drove most of the sequential decline; Southeast Asia Pacific grew net sales 2% after a 13% decline the prior quarter.
- Growing active customers is the top priority, through brand investment, incentive refinements and product innovation launching in 2027 (women's and kids' initiatives).
- Hiya: active monthly subscribers up 18% sequentially (about 29,500 net adds) as acquisition costs fell; Target and Amazon sales more than doubled from Q2; Hiya sales outlook raised to $130 million; club retail entry planned early Q1 2027.
- Rise Wellness: outlook lowered again because club orders are lumpy; Protein Pop Balance launched at Target; about 4,100 Target and grocery stores by year end.
- Outlook (Hekking): net sales approaching $900 million, adjusted EBITDA about $77 million (previously $80.5 million); Core Nutritional sales about $740 million.
- Cash: $45 million operating cash flow and $36 million free cash flow year to date; $179 million cash and no debt.
- Brand Partner plan: adjustments to qualification criteria and payout timing to drive retention, phased in through 2027.

## Questions about USANA Health Sciences

### What does USANA Health Sciences do?

It develops and manufactures science-based nutritional supplements, functional foods and personal care products, sold through direct selling (Brand Partners), Hiya's direct-to-consumer subscriptions, Amazon and retail.

### What is USANA's revenue?

FY2025 net sales were $925.3 million. The FY2026 outlook is net sales approaching $900 million.

### How many employees does USANA have?

Approximately 1,570 employees (FTE) in 22 countries, 41% in the United States and 28% in China.

### Who leads USANA?

Kevin Guest reassumed the CEO role in January 2026 and remains Chairman; G. Douglas Hekking is CFO and Walter Noot is COO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
